Martine Rothblatt, who serves as chairperson and CEO of United Therapeutics (NASDAQ: UTHR), executed a series of transactions on April 9, 2026, that together amounted to $5.5 million in common stock sales. The dispositions were made through a pre-arranged 10b5-1 trading plan and comprised multiple trades at prices between $575.0355 and $581.45 per share.
Under the trading plan, Rothblatt sold a total of 8,490 shares of United Therapeutics common stock. The plan was adopted on November 7, 2025, and is slated to remain in effect until either 1,734,410 stock options are exercised or December 31, 2026, whichever occurs first.
On the same day as the sales, Rothblatt exercised stock options to acquire 9,500 shares of United Therapeutics common stock at an exercise price of $146.03 per share, for a total value of $1387285.
Following these transactions, Rothblatt directly holds 40,513 shares of United Therapeutics common stock. She also retains indirect ownership through various trusts.
Outside of Rothblatt's personal transactions, United Therapeutics reported several material developments affecting its clinical and commercial outlook. The U.S. Food and Drug Administration granted a Regenerative Medicine Advanced Therapy designation to miroliverELAP, an investigational liver assist device developed by Miromatrix Medical Inc. The device is intended to provide temporary liver support for patients with acute liver failure.
In addition to the regulatory milestone for the liver assist device, Wall Street analysts updated their views on United Therapeutics in response to positive trial data for Tyvaso in idiopathic pulmonary fibrosis (IPF). H.C. Wainwright raised its price target to $660, citing robust data from the TETON-1 trial. BofA Securities increased its target to $626 while maintaining a Neutral rating. Jefferies established a $733 price target and reported an increased probability of success for Tyvaso's IPF indication. Raymond James initiated coverage with an Outperform rating and set a $700 price target, highlighting projections that Tyvaso could reach more than $5 billion in peak sales.
These developments have prompted a wave of analyst reassessments and underscore market attention on United Therapeutics' pipeline and commercial potential. For readers seeking a deeper dive into valuation and executive activity, the firm's Pro Research Report is available on InvestingPro.
The sequence of insider sales, option exercises, regulatory recognition for a partnered device, and multiple analyst target adjustments together form the most recent public signals about United Therapeutics' prospects. Investors monitoring insider activity, regulatory progress, and analyst expectations will likely view these items as connected elements in assessing the company's near-term and longer-term outlook.